Abstract |
This study explores the imaging and therapeutic properties of a novel radiopharmaceutical, (131)I-CLR1404. Phase 1a data demonstrated safety and tumor localization by SPECT-CT. This 1b study assessed safety, imaging characteristics, and possible antineoplastic properties and provided further proof-of-concept of phospholipid ether analogues' retention within tumors. A total of 10 patients received (131)I-CLR1404 in an adaptive dose-escalation design. Imaging characteristics were consistent with prior studies, showing tumor uptake in primary tumors and metastases. At doses of 31.25 mCi/m(2) and greater, DLTs were thrombocytopenia and neutropenia. Disease-specific studies are underway to identify cancers most likely to benefit from (131)I-CLR1404 monotherapy.
|
Authors | Sam Joseph Lubner, Jacqueline Mullvain, Scott Perlman, Michael Pishvaian, Joanne Mortimer, Katherine Oliver, Jennifer Heideman, Lance Hall, Jamey Weichert, Glenn Liu |
Journal | Cancer investigation
(Cancer Invest)
Vol. 33
Issue 10
Pg. 483-9
( 2015)
ISSN: 1532-4192 [Electronic] England |
PMID | 26536061
(Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- CLR1404
- Iodobenzenes
- Phospholipid Ethers
|
Topics |
- Adult
- Aged
- Drug Discovery
- Female
- Humans
- Iodobenzenes
(administration & dosage, pharmacology, therapeutic use)
- Male
- Middle Aged
- Neoplasms
(drug therapy, radiotherapy)
- Phospholipid Ethers
(administration & dosage, pharmacology, therapeutic use)
- Recurrence
|